TORONTO, ONTARIO--(Marketwired - May 21, 2014) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of new RepaGyn® Hormone-Free Vaginal Suppositories.
RepaGyn® (sodium hyaluronate) is an innovative vaginal suppository recommended for the healing of the vaginal mucosa and the treatment of vaginal dryness caused by menopause, stress and chemotherapy. It is also recommended in situations where tissue repair is required after invasive vaginal surgeries and biopsy procedures. RepaGyn® vaginal suppositories can be used with or without local hormone therapy.
RepaGyn® is formulated with sodium hyaluronate, a naturally occurring compound, and offers a hormone-free treatment alternative proven to deliver symptom relief, restoration of pH balance, and tissue repair in one ovule. RepaGyn® has established clinical evidence of both efficacy and symptom relief and has been recommended by doctors and successfully used by women in several European countries including Italy, France, Belgium, Switzerland, Denmark and Poland for over 10 years under the brand names Cicatridine®, Cicatridina®, Cikatridina®, and Repadina®.
"The launch of RepaGyn® is an important milestone in the development of the BioSyent Pharma business," commented René Goehrum, CEO of BioSyent. "The product itself is consistent with our strategy of sourcing unique products that address unmet medical needs for the Canadian healthcare market, and represents a further broadening of our portfolio. The patient population that can benefit from RepaGyn® is significant."
RepaGyn® is approved by Health Canada and was in-licensed by BioSyent Pharma for exclusive marketing and distribution in Canada from FARMA-DERMA s.r.l., Italy in October of 2013. Shipments to wholesalers and pharmacies will commence in June 2014.
To learn more about RepaGyn®, please visit the website www.RepaGyn.ca.
For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.
At the date of this press release the Company had 13,776,195 shares issued and outstanding.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.